PDCD1 and in situ carcinoma: In January 2020, the FDA approved pembrolizumab, a monoclonal antibody targeting the programmed cell death protein 1 (PD‐1), for the treatment of patients with BCG‐unresponsive, high‐risk, NMIBC with CIS with or without papillary disease who are ineligible for or have elected not to undergo ERC.23